|
News / Headlines
Panasonic Sponsors SHAPE Symposium on Cardiovascular Imaging of
Asymptomatic Atherosclerosis - Coronary Calcium and Carotid IMT
The SHAPE Prevention Summit 2009 Focuses on Screening of the
Asymptomatic Population: From Guidelines to Legislation to Practice
"Our job is far from done. We must now embark on educating both
physicians and patients on what to do with the results of the test.
No diagnostic test saves life; it is the therapeutic interventions
after testing that makes the difference."
"The passage of the first preventive cardiovascular screening bill
can open a new path in preventive cardiovascular care, the
implications of which can go beyond Texas."
Houston, Texas (PRWEB) October 18, 2009 -- The passage of the first
Heart Attack Preventive Screening Bill in Texas (HB1290) has created
a great interest among physicians and patients to learn more about
heart attack preventive screening. The Society for Heart Attack
Prevention and Eradication (SHAPE), which supported passing the law,
is an organization guided by world renowned cardiovascular
specialists, researchers, patient volunteers, and preventive
healthcare advocates who are drawn together by the vision of
eradicating heart attacks. In continuing its educational activities,
the SHAPE organization will be holding its 18th educational event in
conjunction with the Annual Scientific Sessions of the American
Heart Association.
SHAPE and its predecessor, the Association for Eradication of Heart
Attack (AEHA), have held 17 symposia to raise awareness of education
and research for early detection of the vulnerable patient, i.e. the
individual at risk of sudden heart attack in the near future. For
the upcoming SHAPE symposium the main focus of the discussions will
be screening for early detection and treatment of asymptomatic
atherosclerotic patients. This year's symposium is particularly
significant since it comes after the passage of the first preventive
cardiovascular screening act, which was passed in Texas. Thus, SHAPE
Task Force members and distinguished cardiovascular specialists will
also embark on educating physicians to practice careful and
responsible implementation of comprehensive heart attack risk
assessment and reduction strategy as mandated in the preventive
screening cardiovascular law.
"This is a monumental legislation that can become a bold milestone
in the history of eradicating heart attacks in decades to come,"
said Dr. Morteza Naghavi, founder of SHAPE, and Chairman of the
SHAPE Task Force who testified at the Texas House of Representative.
"Our job is far from done. We must now embark on educating both
physicians and patients on what to do with the results of the test.
No diagnostic test saves life; it is the therapeutic interventions
after testing that makes the difference."
In the early spring of 2010, the first preventive cardiovascular
screening act is poised to go into effect in Texas. The legislation
will require reimbursement of up to $200 for either a non-contrast
computer tomography (CT) scan measuring coronary artery
calcification, commonly known as calcium scoring exam, or
ultrasonography measuring carotid intima-media thickness and plaque.
It will benefit men, between ages 45 and 75, and women, between ages
55 and 75, who are at intermediate risk of a heart attack according
to their Framingham Risk Score.
"The passage of the first preventive cardiovascular screening bill
can open a new path in preventive cardiovascular care, the
implications of which can go beyond Texas," said Dr. P.K. Shah,
Director of Cardiology at Cedars Sinai Heart Institute in Los
Angeles, a principal member of the SHAPE Task Force and an active
member of the American Heart Association.
The SHAPE symposium will be held in Orlando, Florida at the Rosen
Plaza at 7-9 PM, November 15, 2009. The event will be co-hosted with
the Society of Atherosclerosis Imaging and Prevention (SAIP) and is
solely sponsored by Panasonic Corporation. Click here to view
agenda.
Register now at
www.shapesociety.org and receive a complimentary Panasonic
BP Monitor.
The SHAPE Prevention Summit 2009 on Screening of the Asymptomatic
Population: From Guidelines to Legislation to Practice
Agenda:
Opening: Morteza Naghavi, M.D.,
Update on the Texas Heart Attack Preventive Screening Law
Moderator: Roger Blumenthal, M.D.
Faculty Panel: Daniel Berman, M.D., Erling Falk, M.D., Ph.D., Harvey
Hecht, M.D., Sanjay Kaul, M.D., Khurram Nasir, M.D., John Rumberger,
M.D., Ph.D., and Leslee Shaw, Ph.D.
Focus: Screening for Early Detection and Treatment of Asymptomatic
Atherosclerotic Patients
SHAPE Preventive Screening: Treatment Should Depend on
Atherosclerosis Rather than Risk Factors of Atherosclerosis
Erling Falk
30 minutes
Carotid IMT Screening
Daniel H. O'Leary
30 minutes
Coronary Calcium Screening
Matthew Budoff, M.D.
30 minutes
Latest in Carotid IMT: Operator-Independent Measurement using
Automated Frequency Domain Analysis
Steve Feinstein, M.D.
30 minutes
Open Floor Discussion
Closing: Roger Blumenthal, M.D.
About SHAPE
Originated from the Texas Medical Center in Houston, the Society for
Heart Attack Prevention and Eradication (SHAPE) is a non-profit
organization founded by Dr. Morteza Naghavi, a former faculty of the
Texas Heart Institute and the University of Texas in Houston. The
mission of SHAPE is to promote education and research related to
mechanism, prevention, detection, and treatment of heart attacks.
The organization is committed to raising public awareness about
recent revolutionary discoveries that opened exciting new avenues to
prevent heart attack. SHAPE's mission is to eradicate heart attacks
in the 21st century. Additional information is available on the
organization's Web site at shapesociety.org or call 1-877-SHAPE11
About SHAPE Task Force
Chairman: Morteza Naghavi, M.D. Editorial Committee: Prediman K.
Shah, M.D. (Chief); (alphabetic order): Raymond Bahr, M.D., Daniel
Berman, M.D., Roger Blumenthal, M.D., Matthew J. Budoff, M.D., Jay
Cohn, M.D., Erling Falk, M.D., Ph.D., Ole Faergeman, M.D., Zahi
Fayad, Ph.D., Harvey S. Hecht, M.D., Wolfgang Koenig, M.D., Ph.D.,
Daniel Lane, M.D., Ph.D., Morteza Naghavi, M.D., John Rumberger,
M.D., Ph.D., Allen J. Taylor, M.D. Writing Group: Erling Falk, M.D.,
Ph.D. (Coordinator); (alphabetic order): Juhani Airaksinen, M.D.,
Dan Arking, Ph.D., Juan Badimon, Ph.D., Raymond Bahr, M.D., Daniel
Berman, M.D., Matthew J. Budoff, M.D., Jay Cohn, M.D., Jasenka
Demirovic, M.D., Ph.D., Pamela Douglas, M.D., Ole Faergeman, M.D.,
Zahi Fayad, Ph.D., James A. Goldstein, M.D., Harvey S. Hecht, M.D.,
Victoria L.M. Herrera, M.D., Sanjay Kaul, M.D., M.P.H., Wolfgang
Koenig, M.D., Ph.D., Robert A. Mendes, M.D., Morteza Naghavi, M.D.;
Tasneem Z. Naqvi, M.D., Ward A. Riley, Ph.D., Yoram Rudy, PhD, John
Rumberger, M.D., Ph.D., Leslee Shaw, Ph.D., Robert S. Schwartz,
M.D., Arturo G. Touchard, M.D. Advisors (alphabetic order): Arthur
Agagston, M.D., Stephane Carlier, M.D., Ph.D., Raimund Erbel, M.D.,
Chris deKorte, Ph.D., Craig Hartley, Ph.D., Ioannis Kakadiaris,
Ph.D., Roxana Mehran, M.D., Ralph Metcalfe, Ph.D., Daniel O'Leary,
M.D., Jan Nilsson, M.D., Gerard Pasterkamp, M.D., Ph.D., Paul
Schoenhagen, M.D., Henrik Sillesen, M.D., Ph.D.
|
